SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
Small Cap Foreign Biotech
An SI Board Since January 2000
Posts SubjectMarks Bans
363 30 0
Emcee:  RWReeves Type:  Unmoderated
Introduction Compact
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
263Nigel, As someone who frequents rattler country on a regular basis, I have thistuck-5/5/2002
262Rattlesnake bite biotech group Protherics (PTH.L) saw a large investor, thought nigel bates-5/1/2002
261Xenova Group plc Potential US$63m (43.2m pounds) Development and License Agreemenigel bates-4/23/2002
260Tuesday April 9, 10:14 am Eastern Time Press Release SOURCE: Procyon Biopharma Ithebeach-4/9/2002
259At low points in the Biotech market, we have a lot of fodder for the BTFLAB millRWReeves-4/5/2002
258Novuspharma SpA Provides Update on Progress With BBR 2778 Phase III Clinical Trinigel bates-4/4/2002
257the release doesn't touch sufficiently on many of the basics..... physiciscaram(o)uche-3/27/2002
256Xenova Group plc Successful Results of Phase IIa Trial For Therapeutic Vaccine Tnigel bates-3/27/2002
255Vernalis contd... <pre> Consolidated profit and loss account for thenigel bates-3/19/2002
254LONDON, March 19 /PRNewswire-FirstCall/ -- Vernalis Group plc (London: VER), thenigel bates-3/19/2002
253Persistent buyers of XNVA... Xenova Group PLC 15 March 2002 In accordance withnigel bates-3/15/2002
252BioMS Medical ANNOUNCES PRELIMINARY RESULTS FROM PHASE II TRIAL Edmonton, AlberBlaumax-3/2/2002
251Xenova Group PLC - Holding(s) in Company RNS Number:1824S 28 February 2002 Lettnigel bates-2/28/2002
25028th February 2002 ReNeuron Announces Collaboration with Proteome Sciences to Idnigel bates-2/28/2002
249(Xenova pt.3) 1 Basis of preparation These unaudited statements, which dnigel bates-2/19/2002
248(Xenova pt.2) For Xenova: Disclaimer to take advantage of the ``Safe Harbor'nigel bates-2/19/2002
247SLOUGH, England, Feb. 19 /PRNewswire-FirstCall/ -- Xenova Group plc (Nasdaq: XNVnigel bates-2/19/2002
246Don't know if there is anything in this, but I'd be very happy if there nigel bates-2/19/2002
245Curious they didn't announce this on the 11th as well ? LONDON, Feb. 13 /PRnigel bates-2/13/2002
244Vernalis is starting to look very interesting. Thanks to the pall cast by Elan, nigel bates-2/11/2002
243<i>Thank you for pointing out what a good strategy it is so far</i> nigel bates-2/10/2002
242>>Now not interested. Nevermind. They did OK on Friday. <g><< keokalani'nui-2/9/2002
241<i>In September 2001, WestLB Panmure predicted</i> I would think thnigel bates-2/9/2002
240Curr Opin Investig Drugs 2001 Nov;2(11):1592-4 NS-2330 (Neurosearch). Thatte Uscaram(o)uche-2/9/2002
239<i>Now not interested. Nevermind.</i> They did OK on Friday. <g&gnigel bates-2/9/2002
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News